Reuben M Tooze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8577178/publications.pdf

Version: 2024-02-01

71 papers

4,457 citations

147801 31 h-index 62 g-index

80 all docs

80 docs citations

80 times ranked 5529 citing authors

#	Article	IF	Citations
1	Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network. Blood Advances, 2022, 6, 5716-5731.	5.2	12
2	A System for In Vitro Generation of Mature Murine Plasma Cells Uncovers Differential <i>Blimp-1</i> Prdm1Promoter Usage. Journal of Immunology, 2022, 208, 514-525.	0.8	1
3	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
4	Application of the LymphGen classification tool to 928 clinically and geneticallyâ€characterised cases of diffuse large B cell lymphoma (DLBCL). British Journal of Haematology, 2021, 192, 216-220.	2.5	28
5	Comparative analysis of gene expression platforms for cellâ€ofâ€origin classification of diffuse large Bâ€cell lymphoma shows high concordance. British Journal of Haematology, 2021, 192, 599-604.	2.5	7
6	Identification of Critical Transcriptomic Signaling Pathways in Patients with H Syndrome and Rosai-Dorfman Disease. Journal of Clinical Immunology, 2021, 41, 441-457.	3.8	4
7	Novel Case of Tripeptidyl Peptidase 2 Deficiency Associated with Mild Clinical Phenotype. Journal of Clinical Immunology, 2021, 41, 1123-1127.	3.8	4
8	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Molecular Cell, 2021, 81, 4059-4075.e11.	9.7	42
9	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. Hepatology, 2021, 74, 2561-2579.	7.3	13
10	B Cell Tetherin: A Flow Cytometric Cellâ€Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 769-779.	5.6	16
11	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia, 2020, 34, 1329-1341.	7.2	66
12	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood, 2020, 135, 1759-1771.	1.4	271
13	TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation. Blood Advances, 2020, 4, 2821-2836.	5.2	5
14	A dichotomy of gene regulatory associations during the activated B-cell to plasmablast transition. Life Science Alliance, 2020, 3, e202000654.	2.8	4
15	Case-based discussion: a case of misdiagnosis of primary lung malignancy. Thorax, 2019, 74, 1003-1005.	5.6	O
16	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABCâ€subtype diffuse large Bâ€eell lymphoma. Journal of Pathology, 2019, 248, 142-154.	4.5	8
17	Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. Leukemia, 2019, 33, 2884-2897.	7.2	26
18	Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer. Npj Systems Biology and Applications, 2019, 5, 13.	3.0	22

#	Article	IF	Citations
19	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 649-662.	10.7	187
20	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. Journal of Clinical Oncology, 2019, 37, 202-212.	1.6	187
21	Cellâ€ofâ€origin in diffuse large Bâ€cell lymphoma: findings from the <scp>UK</scp> 's populationâ€based Haematological Malignancy Research Network. British Journal of Haematology, 2019, 185, 781-784.	2.5	19
22	Growth Factor–like Gene Regulation Is Separable from Survival and Maturation in Antibody-Secreting Cells. Journal of Immunology, 2019, 202, 1287-1300.	0.8	11
23	A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Scientific Reports, 2018, 8, 5793.	3.3	70
24	Highly selective <scp>SYK</scp> inhibitor, <scp>GSK</scp> 143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 182, 927-930.	2.5	1
25	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia, 2018, 32, 214-223.	7.2	25
26	Biallelic interferon regulatory factor 8 mutation: AÂcomplex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation. Journal of Allergy and Clinical Immunology, 2018, 141, 2234-2248.	2.9	63
27	Site-1 protease function is essential for the generation of antibody secreting cells and reprogramming for secretory activity. Scientific Reports, 2018, 8, 14338.	3.3	24
28	Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. Journal of Immunology, 2017, 198, 4618-4628.	0.8	40
29	A category-free approach to prognostic modelling in aggressive non-Hodgkin B cell lymphomas based on large patient databases. Hematological Oncology, 2017, 35, 326-327.	1.7	0
30	Prdm1 Regulates Thymic Epithelial Function To Prevent Autoimmunity. Journal of Immunology, 2017, 199, 1250-1260.	0.8	53
31	THU0293â€B-cell responses to type I interferon define disease activity in SLE and can be measured by cell surface tetherin (CD317)., 2017,,.		0
32	THU0013â€Normal CD19-Negative Plasma Cells Are Biologically Distinct from Other Normal Plasma Cells and Likely To Be Involved in Lack of Response To B-Cell Depletion for Autoimmune Disorders. Annals of the Rheumatic Diseases, 2016, 75, 182.1-182.	0.9	0
33	THU0002â€Prevalence of Monoclonal B-Cell Disorders in Patients with Autoimmunity in The UK. Annals of the Rheumatic Diseases, 2016, 75, 178.2-178.	0.9	0
34	Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. Journal of Immunology, 2016, 197, 1447-1459.	0.8	52
35	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. Cancer Research, 2016, 76, 6975-6987.	0.9	21
36	Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Medicine, 2015, 7, 64.	8.2	20

3

#	Article	IF	CITATIONS
37	Blimpâ€1 homolog Hobit identifies effectorâ€type lymphocytes in humans. European Journal of Immunology, 2015, 45, 2945-2958.	2.9	94
38	Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Molecular Cancer, 2015, 14, 205.	19.2	24
39	Gene expression meta-analysis reveals immune response convergence on the IFNÎ ³ -STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Medicine, 2015, 7, 96.	8.2	24
40	Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). Blood, 2015, 126, 331-331.	1.4	0
41	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Research, 2014, 42, 7591-7610.	14.5	43
42	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood, 2014, 124, 3118-3129.	1.4	35
43	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. Journal of Autoimmunity, 2014, 50, 59-66.	6.5	59
44	A Replicative Self-Renewal Model for Long-Lived Plasma Cells: Questioning Irreversible Cell Cycle Exit. Frontiers in Immunology, 2013, 4, 460.	4.8	28
45	A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma. PLoS ONE, 2013, 8, e55895.	2.5	64
46	Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large <scp>B</scp> â€ell lymphoma and predict clinical outcome. British Journal of Haematology, 2012, 159, 441-453.	2.5	81
47	In Vitro Generation of Long-lived Human Plasma Cells. Journal of Immunology, 2012, 189, 5773-5785.	0.8	111
48	BLIMP-1 and STAT3 Counterregulate MicroRNA-21 during Plasma Cell Differentiation. Journal of Immunology, 2012, 189, 253-260.	0.8	44
49	Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. Laboratory Investigation, 2011, 91, 1298-1303.	3.7	8
50	An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Research, 2010, 38, 5336-5350.	14.5	52
51	Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica, 2009, 94, 419-422.	3. 5	27
52	Amino Acid Deprivation Links BLIMP-1 to the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase. Journal of Immunology, 2009, 183, 5768-5777.	0.8	22
53	An Expanded Set of Direct BLIMP-1 Targets Identifies Novel Links in Differentiation, Immune Response and Lymphoma Blood, 2009, 114, 1466-1466.	1.4	0
54	Reprogramming Primordial Germ Cells into Pluripotent Stem Cells. PLoS ONE, 2008, 3, e3531.	2.5	140

#	Article	IF	Citations
55	Feedback inhibition of indoleamine 2,3â€dioxygenase by BLIMPâ€1 in response to tryptophan depletion. FASEB Journal, 2008, 22, 1065.20.	0.5	0
56	PRDM1/BLIMP-1 Modulates IFN- \hat{l}^3 -Dependent Control of the MHC Class I Antigen-Processing and Peptide-Loading Pathway. Journal of Immunology, 2007, 179, 7614-7623.	0.8	40
57	Eosinophilic Bowel Disease Controlled by the BB Rat-Derived Lymphopenia/Gimap5 Gene. Gastroenterology, 2006, 131, 1475-1485.	1.3	34
58	Blimp1 Defines a Progenitor Population that Governs Cellular Input to the Sebaceous Gland. Cell, 2006, 126, 597-609.	28.9	396
59	BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. European Journal of Immunology, 2006, 36, 1572-1582.	2.9	48
60	Repression of IFN- \hat{I}^3 Induction of Class II Transactivator: A Role for PRDM1/Blimp-1 in Regulation of Cytokine Signaling. Journal of Immunology, 2006, 177, 4584-4593.	0.8	28
61	BLIMP-1 Is a Target of Cellular Stress and Downstream of the Unfolded Protein Response Blood, 2005, 106, 2207-2207.	1.4	0
62	MHC Class-II Expression Reveals Differential Regulation of BLIMP-1 Target Genes Blood, 2005, 106, 1207-1207.	1.4	20
63	Malignant adenomyoepithelioma of the breast metastasizing to the liver. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 504-506.	2.8	40
64	Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene, 2003, 22, 7750-7761.	5.9	66
65	An unusual late relapse. International Journal of Laboratory Hematology, 2001, 23, 197-199.	0.2	1
66	Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. Nature Immunology, 2001 , 2 , 542 - 547 .	14.5	169
67	Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. EMBO Journal, 2000, 19, 4644-4654.	7.8	48
68	CD19 as a Membrane-Anchored Adaptor Protein of B Lymphocytes: Costimulation of Lipid and Protein Kinases by Recruitment of Vav. Immunity, 1998, 8, 635-645.	14.3	177
69	Counterregulation by the Coreceptors CD19 and CD22 of MAP Kinase Activation by Membrane Immunoglobulin. Immunity, 1997, 7, 59-67.	14.3	115
70	Co-receptors of B lymphocytes. Current Opinion in Immunology, 1997, 9, 324-329.	5.5	75
71	Sequential Inverse Dysregulation of the RNA Helicases DDX3X and DDX3Y Facilitates MYC-Driven Lymphomagenesis. SSRN Electronic Journal, 0, , .	0.4	2